Design, selection, and evaluation of a general kinase-focused library

ChemMedChem

Volumn 4, Issue 8, 2009, Pages 1273-1278

  Decornez, Hélène ^a   Gulyás Forró, Anna ^b,e   Papp, Ákos ^b,f   Szabó, Miklós ^b   Sármay, Gabriella ^c   Hajdú, István ^d   Cseh, Sándor ^d   Dormán, György ^b,d   Kitchen, Douglas B ^a  

^a ALBANY MOLECULAR RESEARCH INC   (United States)

^b AMRI   (Hungary)

^c EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^d TargetEx   (Hungary)

^e Wessling Hungary Ltd   (Hungary)

^f ChemAxon Ltd   (Hungary)

Author keywords

General kinase model; Kinase focused library; Similarity; Virtual screening

Indexed keywords

PHOSPHOTRANSFERASE;

ARTICLE; CATALYSIS; CRYSTAL STRUCTURE; ENZYME ACTIVITY; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; SCREENING;

CATALYTIC DOMAIN; COMBINATORIAL CHEMISTRY TECHNIQUES; COMPUTER SIMULATION; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DATABASES, FACTUAL; DRUG DESIGN; ENZYME INHIBITORS; PHOSPHOTRANSFERASES; PROTEIN BINDING;

EID: 68149149021     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200900164     Document Type: Article

References (37)

1. G. Manning, D. B. Whyte, R. Martinez, T. Hunter, S. Sudarsanam, Science 2002, 298, 1912-1934.
2. B. S. Edwards, C. Bologa, S. M. Young, K. V. Balakin, E. R. Prossnitz, N. P. Savchuck, L. A. Sklar, T. I. Oprea, Mol. Pharmacol. 2005, 68, 1301-1310.
3. O. Prien, ChemBioChem 2005, 6, 500-505.
4. T. Polgar, A. Baki, G. I. Szendrei, and G. M. Keser, J. Med. Chem. 2005, 48, 7946-7959.
5. D. M. Schnur, M. A. Hermsmeier, A. J. Tebben, J. Med. Chem. 2006, 49, 2000-2009.
6. M. A. Fabian, W. H. Biggs III, D. K. Treiber, C. E. Atteridge, M. D. Azimioara, M. G. Benedetti, T. A. Carter, P. Ciceri, P. T. Edeen, M. Floyd, J. M. Ford, M. Galvin, J. L. Gerlach, R. M. Grotzfeld, S. Herrgard, D. E. Insko, M. A. Insko, A. G. Lai, J. M. Lélias, S. A. Mehta, Z. V. Milanov, A. M. Velasco, L. M. Wodicka, H. K. Patel, P. P. Zarrinkar, D. J. Lockhart, Nat. Biotechnol. 2005, 23, 329-336.
7. M. W. Karaman, S. Herrgard, D. K. Treiber, P. Gallant, C. E. Atteridge, B. T. Campbell, K. W. Chan, P. Ciceri, M. I. Davis, P. T. Edeen, R. Faraoni, M. Floyd, J. P. Hunt, D. J. Lockhart, Z. V. Milanov, M. J. Morrison, G. Pallares, H. K. Patel, S. Pritchard, L. M. Wodicka, P. P. Zarrinkar, Nat. Biotechnol. 2008, 26, 127-132.
8. E. ter Haar, Mini-Rev. Med. Chem. 2004, 4, 235-253.
9. T. Fojo, Oncologist, 2008, 13, 277-283.
10. A. Tovar, H. Eckert, J. Bajorath, ChemMedChem 2007, 2, 208-217.
11. P. Willett, J. Med. Chem. 2005, 48, 4183-4199.
12. L. Xue, J. Godden, H. Gao, J. Bajorath, J. Chem. Inf. Comput. Sci. 1999, 39, 699-704.
13. CMC-3D (Comprehensive Medicinal Chemistry Database), version 99.1, MDL Information Systems Inc., 14600 Catalina Street, San Leandro, CA (USA).
14. Synthline Drug Database on STN International, taken from Drugs of the Future (comprehensive drug monographs, Prous Science), 1984-present, Prous Science, Provenza 388, Barcelona (Spain) http://www.prous.com/databases/ synthweb/synthweb.html (accessed May 21, 2009).
15. Ensemble, Prous Science, 2002, http://www.prous.com (accessed May 21, 2009).
16. H. Eckert, J. Bajorath, Drug Discovery Today 2007, 12, 225-233.
17. P. Willett, Drug Discovery Today 2006, 11, 1046-1053.
18. ChemAxon version 2.2, 2008, http://www.chemaxon.com (accessed May 21, 2009);
19. JChem Base was used for structure searching and chemical database access and management: JChem v. 3.2.12, 2008;
20. Marvin was used for drawing, displaying, and characterizing chemical structures and substructures: Marvin v. 4.1.14, 2008; fingerprints are explained at: http://www.chemaxon.com/jchem/doc/user/fingerprint.html (accessed May 21, 2009).
21. S. E. Adams, R. C. Glen, QSAR Comb. Sci. 2007, 26, 1133-1142.
22. R. Gozalbes, L. Simon, N. Froloff, E. Sartori, C. Monteils, R. Baudelle J. Med. Chem. 2008, 51, 3124-3132.
23. N. Narayana, T. C. Diller, K. Koide, M. E. Bunnage, K. C. Nicolaou, L. L. Brunton, N. H. Xuong, L. F. Ten Eyck, S. S. Taylor, Biochemistry 1999, 38, 2367-2376.
24. Glide version 40217, Schrödinger, LLC, New York, NY (USA).
25. The docking mode of Glide was used with the following parameters modified: maxconf=1000, maxkeep=5000, and maxref=1000.
26. R. A. Friesner, J. L. Banks, R. B. Murphy, T. A. Halgren, J. J. Klicic, D. T. Mainz, M. P. Repasky, E. H. Knoll, M. Shelley, J. K. Perry, D. E. Shaw, P. Francis, P. S. Schenkin, J. Med. Chem. 2004, 47, 1739-1749.
27. T. A. Halgren, R. B. Murphy, R. A. Friesner, H. S. Beard, L. L. Pollard, J. L. Banks, J. Med. Chem. 2004, 47, 1750-1759.
28. R. A. Friesner, R. B. Murphy, M. P. Repasky, L. L. Frye, J. R. Greenwood, T. A. Halgren, P. C. Sanschagrin, D. T. Mainz, J. Med. Chem. 2006, 49, 6177-6196.
29. H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov, P. E. Bourne, Nucleic Acids Res. 2000, 28, 235-242.
30. T. Liu, Y. Lin, X. Wen, R. N. Jorissen, M. K. Gilson, Nucleic Acids Res. 2007, 35 (Database Issue), D198-D201.
31. D. S. Wishart, C. Knox, A. C. Guo, S. Shrivastava, M. Hassanali, P. Stothard, Z. Chang, J. Woolsey, Nucleic Acids Res. 2006, 34 (Database Issue), 668-672.
32. A. M. Aronov, M. A. Murcko, J. Med. Chem. 2004, 47, 5616-5619.
33. A. M. Aronov, B. McClain, C. S. Moody, M. A. Murcko, J. Med. Chem. 2008, 51, 1214-1222.
34. The number of compounds docked is the number of compounds that pass the default docking filters (<100 atoms, <15 rotatable bonds, and no invalid atom types for the OPLS2001 force-field) and are thus smaller than the initial dataset size. For example, of the 150 reference compounds, eight were not docked due to the presence of too many rotatable bonds, giving a final set of 142 compounds which were evaluated by molecular docking.
35. To identify ligand structures that are known protein kinase binders within the PDB, a set of five protein kinase crystal structures were identified as true protein kinase domains representing key sequences in the protein kinase family and used as reference sequences. The structures were 1ATP, 1NVR, 1OKY, 1QPD and 2BUJ. The co-crystal complexes with sequence identities of at least 20% over a span of at least 200 amino acids to the reference sequences were assumed to be true protein kinase structures, and their ligands true kinase binding molecules. Ligands co-crystallized with these kinase structures were extracted, and structures were eliminated if they contained undesirable elements, were trivial co-solvent molecules, ions or ATP-like compounds (consisting of an adenine or guanidine linked to a sugar moiety). This procedure ensured that our dataset consisted of ligands binding in the active site of protein or receptor kinases.
36. H. Mischak, A. Bodenteich, W. Kolch, J. Goodnight, F. Hofer, F. J. Mushinski, Biochemistry 1991, 30, 7925-7931.
37. A quinazoline modification of this scaffold was present in our reference set.